vs
亚玛芬体育（AS）与阿普塔集团（ATR）财务数据对比。点击上方公司名可切换其他公司
亚玛芬体育的季度营收约是阿普塔集团的1.1倍（$1.1B vs $962.7M），阿普塔集团净利率更高（7.7% vs 1.8%，领先5.9%），阿普塔集团自由现金流更多（$96.9M vs $92.2M）
亚玛芬体育是芬兰跨国运动装备企业，总部位于赫尔辛基，成立于1950年。早年为涉足烟草贸易、航运、出版等领域的多元化工业集团，后逐步转型专注于体育用品的生产与营销，现有员工超9700人，2018年起成为中国安踏体育旗下子公司。
阿普塔集团（AptarGroup, Inc.）是总部位于美国的全球性制造企业，主营消费品分配包装产品及药物给药装置的研发与生产，目前在全球18个国家设有生产运营基地，服务医药、快消等多领域客户。
AS vs ATR — 直观对比
营收规模更大
AS
是对方的1.1倍
$962.7M
净利率更高
ATR
高出5.9%
1.8%
自由现金流更多
ATR
多$4.7M
$92.2M
损益表 — Q1 FY2024 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.1B | $962.7M |
| 净利润 | $19.0M | $74.3M |
| 毛利率 | 52.8% | — |
| 营业利润率 | 12.4% | 11.0% |
| 净利率 | 1.8% | 7.7% |
| 营收同比 | — | 13.5% |
| 净利润同比 | — | -26.4% |
| 每股收益（稀释后） | $0.05 | $1.13 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASATR
| Q4 25 | — | $962.7M | ||
| Q3 25 | — | $961.1M | ||
| Q2 25 | — | $966.0M | ||
| Q1 25 | — | $887.3M | ||
| Q4 24 | — | $848.1M | ||
| Q3 24 | — | $909.3M | ||
| Q2 24 | — | $910.1M | ||
| Q1 24 | $1.1B | $915.4M |
净利润ASATR
| Q4 25 | — | $74.3M | ||
| Q3 25 | — | $127.9M | ||
| Q2 25 | — | $111.7M | ||
| Q1 25 | — | $78.8M | ||
| Q4 24 | — | $100.9M | ||
| Q3 24 | — | $100.0M | ||
| Q2 24 | — | $90.5M | ||
| Q1 24 | $19.0M | $83.1M |
毛利率ASATR
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 52.8% | — |
营业利润率ASATR
| Q4 25 | — | 11.0% | ||
| Q3 25 | — | 14.2% | ||
| Q2 25 | — | 14.9% | ||
| Q1 25 | — | 12.8% | ||
| Q4 24 | — | 14.2% | ||
| Q3 24 | — | 15.2% | ||
| Q2 24 | — | 13.8% | ||
| Q1 24 | 12.4% | 12.2% |
净利率ASATR
| Q4 25 | — | 7.7% | ||
| Q3 25 | — | 13.3% | ||
| Q2 25 | — | 11.6% | ||
| Q1 25 | — | 8.9% | ||
| Q4 24 | — | 11.9% | ||
| Q3 24 | — | 11.0% | ||
| Q2 24 | — | 9.9% | ||
| Q1 24 | 1.8% | 9.1% |
每股收益（稀释后）ASATR
| Q4 25 | — | $1.13 | ||
| Q3 25 | — | $1.92 | ||
| Q2 25 | — | $1.67 | ||
| Q1 25 | — | $1.17 | ||
| Q4 24 | — | $1.48 | ||
| Q3 24 | — | $1.48 | ||
| Q2 24 | — | $1.34 | ||
| Q1 24 | $0.05 | $1.23 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $409.5M |
| 总债务越低越好 | — | $1.1B |
| 股东权益账面价值 | — | $2.7B |
| 总资产 | — | $5.3B |
| 负债/权益比越低杠杆越低 | — | 0.43× |
8季度趋势，按日历期对齐
现金及短期投资ASATR
| Q4 25 | — | $409.5M | ||
| Q3 25 | — | $264.8M | ||
| Q2 25 | — | $169.8M | ||
| Q1 25 | — | $136.8M | ||
| Q4 24 | — | $226.2M | ||
| Q3 24 | — | $327.9M | ||
| Q2 24 | — | $223.9M | ||
| Q1 24 | — | $201.1M |
总债务ASATR
| Q4 25 | — | $1.1B | ||
| Q3 25 | — | $546.0M | ||
| Q2 25 | — | $535.1M | ||
| Q1 25 | — | $561.2M | ||
| Q4 24 | — | $688.1M | ||
| Q3 24 | — | $822.7M | ||
| Q2 24 | — | $681.5M | ||
| Q1 24 | — | $680.4M |
股东权益ASATR
| Q4 25 | — | $2.7B | ||
| Q3 25 | — | $2.8B | ||
| Q2 25 | — | $2.7B | ||
| Q1 25 | — | $2.5B | ||
| Q4 24 | — | $2.5B | ||
| Q3 24 | — | $2.5B | ||
| Q2 24 | — | $2.4B | ||
| Q1 24 | — | $2.3B |
总资产ASATR
| Q4 25 | — | $5.3B | ||
| Q3 25 | — | $5.1B | ||
| Q2 25 | — | $4.9B | ||
| Q1 25 | — | $4.5B | ||
| Q4 24 | — | $4.4B | ||
| Q3 24 | — | $4.6B | ||
| Q2 24 | — | $4.5B | ||
| Q1 24 | — | $4.4B |
负债/权益比ASATR
| Q4 25 | — | 0.43× | ||
| Q3 25 | — | 0.20× | ||
| Q2 25 | — | 0.20× | ||
| Q1 25 | — | 0.22× | ||
| Q4 24 | — | 0.28× | ||
| Q3 24 | — | 0.32× | ||
| Q2 24 | — | 0.28× | ||
| Q1 24 | — | 0.29× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $114.3M | $183.7M |
| 自由现金流经营现金流 - 资本支出 | $92.2M | $96.9M |
| 自由现金流率自由现金流/营收 | 8.8% | 10.1% |
| 资本支出强度资本支出/营收 | 2.1% | 9.0% |
| 现金转化率经营现金流/净利润 | 6.02× | 2.47× |
| 过去12个月自由现金流最近4个季度 | — | $299.6M |
8季度趋势，按日历期对齐
经营现金流ASATR
| Q4 25 | — | $183.7M | ||
| Q3 25 | — | $177.6M | ||
| Q2 25 | — | $126.0M | ||
| Q1 25 | — | $82.7M | ||
| Q4 24 | — | $178.2M | ||
| Q3 24 | — | $229.3M | ||
| Q2 24 | — | $143.6M | ||
| Q1 24 | $114.3M | $92.3M |
自由现金流ASATR
| Q4 25 | — | $96.9M | ||
| Q3 25 | — | $114.3M | ||
| Q2 25 | — | $62.5M | ||
| Q1 25 | — | $25.9M | ||
| Q4 24 | — | $112.2M | ||
| Q3 24 | — | $162.7M | ||
| Q2 24 | — | $75.4M | ||
| Q1 24 | $92.2M | $16.7M |
自由现金流率ASATR
| Q4 25 | — | 10.1% | ||
| Q3 25 | — | 11.9% | ||
| Q2 25 | — | 6.5% | ||
| Q1 25 | — | 2.9% | ||
| Q4 24 | — | 13.2% | ||
| Q3 24 | — | 17.9% | ||
| Q2 24 | — | 8.3% | ||
| Q1 24 | 8.8% | 1.8% |
资本支出强度ASATR
| Q4 25 | — | 9.0% | ||
| Q3 25 | — | 6.6% | ||
| Q2 25 | — | 6.6% | ||
| Q1 25 | — | 6.4% | ||
| Q4 24 | — | 7.8% | ||
| Q3 24 | — | 7.3% | ||
| Q2 24 | — | 7.5% | ||
| Q1 24 | 2.1% | 8.3% |
现金转化率ASATR
| Q4 25 | — | 2.47× | ||
| Q3 25 | — | 1.39× | ||
| Q2 25 | — | 1.13× | ||
| Q1 25 | — | 1.05× | ||
| Q4 24 | — | 1.77× | ||
| Q3 24 | — | 2.29× | ||
| Q2 24 | — | 1.59× | ||
| Q1 24 | 6.02× | 1.11× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AS
| Americas2 | $409.6M | 39% |
| EMEA1 | $356.9M | 34% |
| Greater China3 | $205.6M | 20% |
| Asia Pacific4 | $78.2M | 7% |
ATR
| Pharma Segment | $833.1M | 87% |
| Other | $129.6M | 13% |
